AA
AVIR icon

ALPS Advisors’s Atea Pharmaceuticals AVIR Stock Holding History

ALPS Advisors’s Portfolio AVIR Stock Details AVIR Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		– Sell
-64,862
Closed -$349K – 1175
2026
Q1 		$349K Buy
64,862
+708
+1% +$3.25K ﹤0.01% 965
2025
Q4 		$229K Buy
64,154
+27,403
+75% +$87.1K ﹤0.01% 960
2025
Q3 		$107K Sell
36,751
-9,414
-20% -$32.1K ﹤0.01% 1017
2025
Q2 		$166K Buy
+46,165
New +$138K ﹤0.01% 1013
2024
Q4 		– Sell
-64,692
Closed -$217K – 997
2024
Q3 		$217K Sell
64,692
-986
-2% -$3.58K ﹤0.01% 977
2024
Q2 		$217K Buy
65,678
+6,311
+11% +$23.5K ﹤0.01% 947
2024
Q1 		$240K Buy
59,367
+931
+2% +$3.64K ﹤0.01% 955
2023
Q4 		$178K Sell
58,436
-3,137
-5% -$9.5K ﹤0.01% 946
2023
Q3 		$185K Buy
61,573
+271
+0.4% +$922 ﹤0.01% 959
2023
Q2 		$229K Buy
61,302
+6,395
+12% +$23.9K ﹤0.01% 964
2023
Q1 		$184K Sell
54,907
-1,705
-3% -$6.92K ﹤0.01% 987
2022
Q4 		$272K Buy
+56,612
New +$286K ﹤0.01% 934

Other funds holding AVIR

Fidelity Investments
Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
BCM
BML Capital Management Zionsville, Indiana $176M AUM 123.21% 1-Year Est. Return
TCM
Tang Capital Management San Diego, California $2.2B AUM 156.35% 1-Year Est. Return
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
BCLSI
Bain Capital Life Sciences Investors Boston, Massachusetts $1.68B AUM 126.09% 1-Year Est. Return
Acadian Asset Management
Acadian Asset Management Boston, Massachusetts $84.2B AUM 55.88% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
Two Sigma Investments
Two Sigma Investments New York $138B AUM 41.87% 1-Year Est. Return

ALPS Advisors's AVIR Position: Q2 2026 in Review

ALPS Advisors sold out of Atea Pharmaceuticals (AVIR) in Q2 2026, closing a stake of 64,862 shares — an estimated $349K sold.

ALPS Advisors first reported a position in AVIR in Q4 2022 and held it in 12 quarters. The position peaked at $349K in Q1 2026. 125 funds tracked by Wall St. Rank hold AVIR as of Q2 2026.

  • ALPS Advisors reported no remaining Atea Pharmaceuticals position as of Q2 2026 after selling out during the quarter.
  • ALPS Advisors sold 64,862 Atea Pharmaceuticals shares in Q2 2026, an estimated $349K.
  • ALPS Advisors first reported a position in Atea Pharmaceuticals in Q4 2022 and held it in 12 quarters.
  • ALPS Advisors's Atea Pharmaceuticals position peaked at $349K in Q1 2026.
  • 125 funds tracked by Wall St. Rank held Atea Pharmaceuticals as of Q2 2026.

Based on ALPS Advisors's 13F filing for Q2 2026, filed 29 Jul 2026.